In a study published by Molecular Oncology journal, and published online by the National Institute of Health, it has been determined the Cannabidiol, a cannabis compound, inhibits growth and metastasis of highly aggressive breast cancer cell lines including triple-negative breast cancer (TNBC) subtype.
According to the researchers from Ohio State University, the non-psychotropic cannabinoid compound, CBD, and its anti-tumorigenic capacity and role especially in TNBC, are not well studied. For the first time, their study has shown how CBD significantly inhibits epidermal growth factor-induced proliferation and chemotaxis of breast cancer cells.
Their analysis showed CBD significantly inhibited the recruitment of tumor-associated macrophages in primary tumor stroma and secondary lung metastasis.
At present, highly aggressive breast cancer subtypes including TNBC, have limited therapeutic options and have low survival rates related to poor prognosis. The results they have documented have given hope which suggests that CBD can be used as a novel therapeutic option to inhibit growth and metastasis of highly aggressive breast cancer subtypes including TNBC.
The researchers concluded their study by showing that CBD inhibits breast cancer growth and metastasis through novel mechanisms by inhibiting EGF/EGFR signaling and modulating tumor microenvironment.